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W
idespread use of combined antiretroviral ther-
apy (cART) has reduced morbidity and mortal-
ity of HIV-infected patients, increasing life expectancy
and quality of life.1 Despite this success, kidney disease
remains a problem in this population with cART asso-
ciated with both acute kidney injury (AKI) and chronic
kidney disease (CKD)2,S1
The incidence of AKI in HIV outpatients ranges from
2.7 to 6.9 per 100 person-years, whereas hospital-related
AKI is between 6% and 18%.2 AKI is commonly multi-
factorial, with volume depletion, sepsis, and drug neph-
rotoxicity the most frequent etiologies.2,3 Drug-induced
nephrotoxicity accounts for up to 30% of AKI episodes
in critically ill patients.S2 There is increasing evidence
that cART can lead to a wide variety of nephrotoxic
effects and mild to severe AKI.4 Many factors contribute
to drug-induced AKI in patients with HIV2; the most
frequent mechanisms of cART nephrotoxicity are sum-
marized in Table 1.2
Herein we report a rare case of severe AKI with
Fanconi-like syndrome associated with cART nephro-
toxicity. Kidney biopsy revealed 2 major forms of
kidney injury: crystalline nephropathy from darunavir
(DRV) and severe proximal tubulopathy due to teno-
fovir disoproxil fumarate (TDF).CASE PRESENTATION
A 61-year-old white man with HIV infection was
admitted to the emergency department with severe AKI
and anemia. The patient had a past history of avascular
necrosis of the left femoral head 3 years prior, when he
refused surgical intervention initiating self-medicationwith nonsteroidal anti-inflammatory drugs; 1 year
later, hypertension and CKD were diagnosed (estimated
glomerular filtration rate 56 ml/min per 1.73 m2). HIV
infection was diagnosed 9 months before admission and
2 months later cART was initiated (he was treatment-
naïve) comprising ritonavir-boosted DRV, TDF, and
emtricitabine. At that time the baseline kidney func-
tion corresponded to 1.63 mg/dl of serum creatinine
with estimated glomerular filtration rate 45 ml/min per
1.73 m2 with no urinary abnormalities. One month before
admission, the patient ingested nonsteroidal anti-
inflammatory drugs for hip pain. Subsequently, he pre-
sented with several days of malaise, anorexia, and fatigue
2 days before admission. Remarkable findings on physical
examination included hypotension, dehydration, marked
pallor, and cachexia.
Laboratory analysis revealed hemoglobin 4.8 g/dl,
ferritin 1400 ng/ml, reticulocytes 5%, serum creatinine
16.3 mg/dl, blood urea nitrogen 161 mg/dl, normal
serum electrolyte, and anion gap metabolic acidosis
(HCO3 13.3, delta HCO3 10.9; anion gap 25.7, delta
anion gap 13.7 mEq/l, and delta delta 1.26 ratio) with
normoglycemia and serum phosphate 6.2 mg/dl. Uri-
nalysis revealed pH 5.5, glucose 1000 mg/dl, and non-
nephrotic proteinuria with urinary protein-creatinine
ratio (0.837 g/g) higher than albumin-creatinine ratio
(0.120 g/g) implying tubular proteinuria; and urinary
hemoglobin (þ3). CD4 was 178 cells/mm3 and viral
load <20 copies RNA/ml.
The patient received 4 units of packed red blood
cells and i.v. saline solution. Metabolic acidosis was
corrected with i.v. bicarbonate and the cART regimen
was modified, withdrawing TDF and beginning
lamivudine.Kidney International Reports (2019) 4, 494–499
Table 1. Causes of AKI in HIV-positive patients and manifestations of antiretroviral toxicity2
Acute kidney injury
Common HIV nonspecific causes
Opportunistic infectionsa
Kidney hypoperfusion and ischemia
Acute interstitial nephritis
Rhabdomyolysis










Inhibition of mitochondrial DNA polymerase;
oxidative phosphorylation and endogenous
nucleotide kinases
AKI, AIN (case report)
Fanconi or Fanconi-like syndrome
Type B lactic acidosis
Nephrogenic diabetes insipidus (case reports)






















Intratubular drug precipitation due to poor solubility
(mainly for indinavir, atazanavir)
AKI and CKD




IIs Raltegravir Skeletal muscle toxicity Rhabdomyolysis and AKI (case reports)
AIN, acute interstitial nephritis; AKI, acute kidney injury; CKD, chronic kidney disease; IIs, integrase inhibitors; NNRTI, non-nucleoside reverse transcriptase inhibitor; NRTI, nucleoside
reverse transcriptase inhibitor; NtRTI, nucleotide reverse transcriptase; PIs, protease inhibitors.
aLess common since cART introduction.
bMore common since cART introduction.
cIncluding antiretroviral drugs listed in Antiretroviral Nephrotoxicity.
K Soto et al.: Tenofovir, Darunavir, and AKI NEPHROLOGY ROUNDSBecause of the lack of kidney recovery, biopsy was
performed 26 days after admission. Light microscopy
showed normal glomeruli, with significant tubular
injury characterized by lumen dilatation, loss of brush
border, and degenerative and reactive features of
tubular cells and detachment of tubular epithelium.
Some vacuoles and empty geometric-like spaces were
also observed in the cytoplasm of tubular cells. There
was stromal edema and sparse inflammatory infiltra-
tion mostly characterized by lymphocytes (Figure 1a,
hematoxylin-eosin original magnification 10). These
lesions affected primarily the proximal tubules.
Granular casts were present in distal tubular lumens
and there was a focal tubulitis with an inflammatory
infiltrate in the interstitium, consisting of lympho-
cytes, plasma cells, and rare eosinophils, but also some
crystals were found inside the cytoplasm of tubular cells
(Figure 1b, hematoxylin-eosin original magnification
10), which were birefringent and multirefractive on
polarized light (Figure 1c, polarized hematoxylin-
eosin original magnification 20). Electron microscopy
confirmed significant proximal tubular injuryKidney International Reports (2019) 4, 494–499characterized by tubular cells with degenerative features
and loss of microvilli. Of note, the cytoplasm contained
plenty of dysmorphic mitochondria, with variations of
size and with a paucity of cristae, some were small with
swollen cristae (Figure 1d, electron microscopy original
magnification 8000). Other ultrastructural findings
included detached epithelial cells, with brush border
effacement and tubular epithelial mitochondria with
irregular shapes and degenerative changes with sparse
abnormal cristae (Figure 1e, electron microscopy original
magnification 5000). Tubular cell lysosomes showed
exuberant needle-shaped and thin lamellar crystals
approximately 5 nm in thickness (Figure 1e, electron
microscopy original magnification 10,000).
The urinary sediment examination was repeated
without centrifugation and a large number of different
crystals were detected by polarized microscopy
(Figure 2a). In addition to calcium oxalate and uric acid
crystals, other irregular crystals were observed that were
most likely DRV. Liquid chromatography with high-
resolution mass spectrometry method was used for
simultaneous identification and quantification of DRV495
Figure 1. Kidney biopsy. Light microscopy: (a) (hematoxylin-eosin [HE], original magnification 10), proximal tubules with lumen dila-
tation, loss of brush border, and degenerative and reactive aspects of tubular cells and detachment of tubular epithelium. Some vacuoles
and empty geometric-like spaces are also observed in the cytoplasm of tubular cells. There is stromal edema and sparse inflammatory
infiltration, mostly characterized by rare lymphocytes. (b) In the center of the image, there is a crystal (arrow) in the cytoplasm of a
tubular cell with lymphocytes permeating through the epithelium, which has degenerative aspect (HE, original magnification 10). (c) The
darunavir crystal is birefringent and multirefractive on polarized light (polarized HE, original magnification 20). Electron microscopy
(EM): (d) Tubular epithelial cells with degenerative aspects and loss of microvilli and cytoplasm containing mitochondria with irregular
shapes, some of them dysmorphic, with variation of size and sparse abnormal cristae and some others smaller with swollen cristae
(original magnification 5000). (e) Tubular cell lysosomes with abundant needle-shaped and thin lamellar crystals, approximately 5 nm in
thickness (EM, original magnification 10,000).
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Figure 2. Urinary crystals. (a) Several crystals are noted under polarized light, including calcium oxalate, uric acid, and darunavir crystals (white
arrows). (b) Liquid chromatography with high-resolution mass spectrometry. Extracted ion chromatograms for darunavir (DRV) in black and
tenofovir (TFV) in red. Urinary crystals contained only DRV in the section marked a, free liquid urine contained both DRV and TFV in b, and
standard solutions of DRV and TFV showing their respective retention times in c. The retention times of DRV and/or TFV in the free liquid urine
and urine crystal were identical to the ones of the standard solutions.
K Soto et al.: Tenofovir, Darunavir, and AKI NEPHROLOGY ROUNDSand tenofovir in the urine sample. Although tenofovir
and DRV were identified in the free liquid urine
(Figure 2b, b section), only DRV was found in the crystal
(Figure 2b, a section). Identification was confirmed on
comparison with standard solutions of tenofovir and DRV
(Figure 2b, c section). More information is found in
Supplementary Table S1.
Based on these findings, DRV was subsequently
withdrawn (36 days of admission) and serum creatinineKidney International Reports (2019) 4, 494–499rapidly decreased to 5.32 mg/dl and reached 2.65 mg/dl
after 5 months. Urine abnormalities also resolved. The
clinical evolution is shown in Figure 3. Of note, there
was no past history of urinary complaints or lithiasis.DISCUSSION
Herein we describe a rare case of severe AKI in a patient









































































cART: DTG & 3TC
Figure 3. Clinical evolution. Changes in serum creatinine level (solid line) and urinary glucose (red columns) since HIV diagnosis and initiation of
combined antiretroviral therapy. Conversion factor for serum creatinine in mg/dl to mol/l 88.4. ART, antiretroviral therapy; cARVT, combined
antiretroviral therapy; DRV/r, darunavir-boosted ritonavir; DTG, dolutegravir; mo, months of evolution; SCr, serum creatinine; TDF, tenofovir;
UrGluc, urinary glucose; 3TC, lamivudine.
NEPHROLOGY ROUNDS K Soto et al.: Tenofovir, Darunavir, and AKIwho developed nephrotoxicity from biopsy-proven
DRV-induced crystalline nephropathy and severe
proximal tubulopathy with mitochondrial injury from
TDF. It is likely that these 2 forms of kidney injury could
have been further exacerbated by exposure to nonste-
roidal anti-inflammatory drugs and underlying CKD.
We first discuss TDF-related kidney injury, which was
manifested as proximal tubulopathy and AKI with
mitochondrial damage noted on kidney biopsy. Based on
ART guidelines, combination therapy with TDF and
emtricitabine has been the first-choice nucleoside reverse
transcriptase inhibitor.S3 However, this combination is
not recommended when creatinine clearance is below 30
to 50 ml/min, as both drugs are mainly eliminated via the
kidneys. In the case reported there was no dose adjust-
ment at ART initiation and therefore the potential
nephrotoxic effect was increased. TDF requires dose
adjustment to avoid tubular toxicity.5 TDF is excreted
unchanged in urine and it is cleared by a combination of
glomerular filtration and proximal tubular secretion.S4
Active transport occurs through basolateral human
organic ion transporter-1 followed by secretion into the
tubular lumen through the apical transporter multidrug
resistance–associated protein 4.6 Dysfunction of efflux
transporters can lead to drug accumulation into the
proximal tubular cellsS5 resulting in high intracellular
concentrations that can deplete mitochondrial DNA and498injure mitochondria.7 Inhibition of basolateral uptake
of TDF may protect against tubular injury by
reducing intracellular concentrations.8 Drug-drug
interactions increase the risk of TDF-related kidney
toxicity by increasing renal exposure to TDF.
Pharmaco-enhancers such as ritonavir increase plasma
concentrations of TDF and increase nephrotoxicity.
Nonsteroidal anti-inflammatory drug intake by our
patient was likely important in decreasing glomerular
filtration rate and further increasing TDF accumula-
tion with development of severe AKI.
As noted in our case, TDF toxicity resulted in se-
vere proximal tubular injury characterized by
glycosuria and tubular proteinuria. Following TDF
withdrawal, kidney function began to recover with
improving proximal tubular function, but AKI only
partially recovered. TDF-induced AKI cases demon-
strate toxic acute tubular necrosis, with distinctive
proximal tubular eosinophilic inclusions representing
giant mitochondria visible by light microscopy and
mitochondrial enlargement, depletion, and dysmor-
phic changes by electron microscopy.7 These same
ultrastructural findings were observed in our case and
noted in other published cases.S6 TDF also causes
chronic tubulointerstitial nephritis and CKD, which
may account for the lack of complete reversibility
observed in our patient.S7Kidney International Reports (2019) 4, 494–499
K Soto et al.: Tenofovir, Darunavir, and AKI NEPHROLOGY ROUNDSThe second kidney lesion noted in our patient was
unexpected, and discovered after review of the kidney
biopsy specimen. The protease inhibitor DRV was
confirmed as the cause of crystalline-induced AKI.
Intratubular crystals and crystals within tubular cell
cytoplasm were observed on light microscopy and within
lysosomes on electron microscopy. Reexamination of the
urine sediment revealed crystals on polarization that
were proven to be DRV on analysis using liquid chro-
matography high-resolution spectrometry. This provided
evidence that supported DRV as the causative crystals in
the tubular lumens and tubular cell lysosomes. Thus, like
the protease inhibitors indinavir and atazanavir, DRV
also can induce crystalline nephropathy.
Protease inhibitors are known to cause kidney injury,
which canmanifest as crystalluria, leukocyturia, nephritis,
nephrolithiasis, nephropathy, and urolithiasis.S8 The pro-
tease inhibitors are poorly soluble in urine and tend to
precipitate in the urine at physiologic pH, in the setting of
volume depletion, underlying kidney disease, and other
factors; however, reports of nephrotoxicity associated
with DRV are quite rare. Ritonavir-boosted DRV has been
associated with increased urinary DRV levels with DRV 13
times higher in the urine than the plasma.9 Of these, 4 of 51
patients treated with ritonavir-boosted DRV had urinary
crystals containing DRV (7.8%), but there were no dif-
ferences in urine and plasma levels of DRV, treatment
duration, or urine pH.9 The incidence of nephrolithiasis is
lower with ritonavir-boosted DRV than ritonavir-boosted
atazanavir, which resulted in the recommendation of its
use in patients at risk for CKD.S9
In conclusion, we report a case of AKI with proximal
tubulopathy due to the dual toxicity of TDF and DRV in
a patient with underlying CKD. Acute tubular injury
and proximal tubulopathy were primarily due to
TDF-induced mitochondrial injury. Further tubular
injury from crystalline-related kidney injury was due to
DRV as manifested by intratubular and cellular DRV
crystals. As such, this is the first report of crystallineTable 2. Teaching points
- ART can lead to a number of nephrotoxic effects including AKI, tubulopathies, and CKD
- Reduced GFR and drug-drug interactions increase the risk of TDF-related kidney toxicity
by increasing renal exposure to tenofovir
- Nonsteroidal anti-inflammatory drugs decrease GFR and further increase ART
accumulation and risk for AKI
- TDF toxicity can result in severe proximal tubular injury, AKI, and CKD
- DRV is another protease inhibitor that is poorly soluble in urine and can cause
crystalline-induced AKI
- Drug discontinuation is mandated to reverse nephrotoxicity
- Urinary sediment analysis should be included in monitoring drugs associated with
crystal formation
- Kidney biopsy is mandatory for diagnosis of ART-induced nephrotoxicity and severe AKI
- High-resolution spectrometry is a useful tool for identification of drug-induced urinary
crystals
AKI, acute kidney injury; ART, antiretroviral therapy; CKD, chronic kidney disease; DRV,
darunavir; GFR, glomerular filtration rate; TDF, tenofovir disoproxil fumarate.
Kidney International Reports (2019) 4, 494–499nephropathy caused by DRV. Health care providers
should be aware of this potential complication when
evaluating patients receiving this drug who develop AKI.
Teaching points are shown in Table 2.
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